Related to Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

• Unigene and GSK Broaden Deal in Anticipation of Phase III Trial in Postmenopausal Osteoporosis
  
• Gilead to Buy Biologics Facility in California from Genentech
  
• FDA Okays Gilead’s San Dimas, CA, Site for Continued Operation
  
• GeoVax Receives Latest Tranche of $19.6M NIAID Funding for HIV Vaccine
  
• GE Healthcare Adds Upstream Bioprocessing Capabilities with Acquisition of PAA Laboratories
  
• Promega Plans 260,000-Square-Foot Facility for Molecular Bio Products
  
• CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand
  
• Sartorius Stedim and GE Healthcare Cross-License Biomanufacturing IP
  
• Ark to Manufacture PsiOxus’ IV-Administered Oncolytic Virus for Clinical Trials
  
• ImmunoCellular Therapeutics Chooses PCT for Supply of Glioblastoma Vaccine Candidate
  
• NIPTE Receives $35M from FDA to Reform Drug Manufacturing Standards
  
• GeoVax and Vivalis Sign Deal for the Biomanufacture of MVA HIV Vaccine in EB66 Cells
  
• ViroPharma Will Buy DuoCort for $33.6M Up Front if EU-Filed Hydrocortisone Drug Is Approved
  
• Repligen Buys Novozymes Biopharma Sweden for $22.7M
  
• GSK Taps Alnylam’s RNAi Technology for Vaccine Production
  
• EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• Aveo Signs BI on as Production Partner for Clinical-Stage mAb
  
• GE Healthcare, M+W to Bolster Biomanufacturing in Emerging Nations
  
• Lonza Expands Small Molecule Manufacturing Facility in China